Who Pays for Sport Horse Science? Kentucky's New Research Complex

Who Pays for Sport Horse Science? Kentucky's New Research Complex

Photo by Matt Barton, University of Kentucky

On October 30, the University of Kentucky cut the ribbon on a new Equine Sports Medicine Research Complex at its North Farm in Lexington. The complex belongs to the Gluck Equine Research Center, and its central machine carries a brand name: the Cosequin Equine Exerciser. According to the university's own release, a gift from Nutramax Laboratories, the company that sells Cosequin joint supplements, funded the new eight-horse exerciser. The other partners named on the project are Keeneland, Spy Coast Farm and Town and Country Farm.

For the hunter/jumper owner, this matters more than a ribbon cutting in Kentucky usually would. The complex exists to study musculoskeletal disease and injury, which the university calls the leading source of economic loss in the equine industry. Its researchers state that degenerative joint disease, or osteoarthritis, represents more than 60% of equine orthopedic cases. It is the condition behind many of the joint injections, supplements and maintenance protocols that show horses receive. The science that comes out of this barn will eventually be quoted back to riders, in veterinary advice and in advertising.

So the question deserves a direct answer. When a company that sells joint supplements pays for the machine on which joint research will be done, what should riders expect from the results?

The Case for Taking the Money

The strongest argument for this arrangement is simple, and it is largely correct: equine research depends heavily on money from the horse industry itself. In 2019, Keeneland gave $1.3 million to the Keeneland Endowed Chair in Equine Veterinary Science at the University of Kentucky, to launch an equine drug research and testing program at the Gluck Center. Britain relies on racing money too. The Horserace Betting Levy Board, which receives no central government grant and is funded by a statutory levy on the horseracing business of bookmakers, is raising its commitment to equine veterinary science research, education and disease surveillance to £3.7 million for the program beginning in 2026, up from £2.76 million in 2025/26.

Bruno Menarim, the Bill Gatton Foundation Endowed Chair in Veterinary Physiology who heads the new complex, has framed its purpose broadly. He said the facility "will provide novel research opportunities that focus on the improvement of equine welfare and safety," and that it will enable "translational, federally funded research opportunities that focus on improving human well-being." The horse is an established model for human musculoskeletal research, and a treadmill does not know who paid for it. The facility is already reserved through 2028.

NHE accepts every part of that argument. A sports medicine barn funded by industry is better than no sports medicine barn at all. The problem lies elsewhere, in what the veterinary literature already shows about sponsored studies.

What the Evidence Says About Sponsored Trials

In 2017, researchers at the University of Nottingham's Centre for Evidence-based Veterinary Medicine published a study in BMC Veterinary Research examining 126 randomized controlled trials of drug interventions in cats, dogs, horses, cattle and sheep. Trials with pharmaceutical funding or involvement reported a positive outcome 56.9% of the time. Trials with non-pharmaceutical funding reported a positive outcome 34.9% of the time, and trials that stated no funding source, 29.1%. Twenty-one of the 126 trials did not report their funding at all. The authors, led by K. J. Wareham, concluded that there was a positive association between pharmaceutical funding or involvement and increased positive outcome reporting.

Joint supplements for horses have their own record. In a 2009 review in the Equine Veterinary Journal, W. Pearson and M. Lindinger examined the entire published in vivo literature on glucosamine-based nutraceuticals for horses, including studies of Cosequin. They found 15 papers, usually on products already commercially available and often seeking evidence for efficacy. Each was scored against preset quality criteria, with 60% set as the minimum for confidence in the results. Only 3 of the 15 met it. The authors called the trend of manufacturers investing in research encouraging, and concluded that the quality of studies in this area was generally low, "prohibiting meaningful interpretation of the reported results."

The risk in sponsored research rarely looks like fraud. It looks like the trial that never gets published, the outcome measure chosen after the data came in, and the small study with no placebo group that ends up quoted on a label.

The figures behind the argument
56.9%: share of pharmaceutically funded veterinary trials reporting a positive outcome (Wareham et al., 2017)
34.9%: the same figure for trials with non-pharmaceutical funding
21 of 126: trials in that study that did not report their funding source
3 of 15: equine glucosamine-based supplement papers that met a 60% quality threshold (Pearson and Lindinger, 2009)
More than 60%: share of equine orthopedic cases attributed to osteoarthritis by the Kentucky researchers

What Should Be Asked of the New Complex

Nothing in the University of Kentucky's announcement suggests any study at the complex will be steered by its sponsors, and NHE makes no such claim. The point is structural. Sponsorship bias works through ordinary choices made by well-intentioned people, and the remedies are equally ordinary.

Human medicine settled the main one long ago. The International Committee of Medical Journal Editors recommends that journals require clinical trials to be registered before enrollment of the first participant, so that the planned outcomes are on public record before anyone sees the data. A complex built to study horses in controlled exercise could adopt the same standard voluntarily, and it should.

Three commitments would make the complex's output easier to trust. Every protocol involving a commercial product should be registered publicly before the first horse is enrolled. Every completed study should be published or posted, including the ones that find nothing. And every paper should state plainly which sponsor, if any, paid for the specific study, rather than the facility it was run in. Britain's Levy Board offers a partial model here: its Veterinary Advisory Committee assesses every application before money is awarded, which places an expert panel between the money and the project.

What Riders Should Do in the Meantime

The research that comes out of Lexington over the next several years will be worth reading. Some of it will show that a product works. Some of it, if the system is honest, will show that a product does not. Riders and trainers can help by asking three questions whenever a supplement, injection or therapy is sold to them on the strength of "university research." Who funded the study? Was it registered before it began? Did it have a placebo or control group, with evaluators who did not know which horses received the treatment?

The sport has every reason to welcome a new sports medicine barn in Kentucky. It also has every reason to read the results with the funding line in view. A horse with osteoarthritis gains nothing from a study that cannot be interpreted, however well equipped the barn it was run in.

0 Kommentare

Hinterlasse einen Kommentar

Bitte beachte, dass Kommentare vor der Veröffentlichung freigegeben werden müssen.